The pretreatment albumin to globulin ratio predicts chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer

被引：61

作者：

Shibutani, Masatsune ^{[1
]}

Maeda, Kiyoshi ^{[1
]}

Nagahara, Hisashi ^{[1
]}

Ohtani, Hiroshi ^{[1
]}

Iseki, Yasuhito ^{[1
]}

Ikeya, Tetsuro ^{[1
]}

Sugano, Kenji ^{[1
]}

Hirakawa, Kosei ^{[1
]}

机构：

[1] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan

来源：

BMC CANCER | 2015年 / 15卷

关键词：

Colorectal cancer; Prognosis; Unresectable; Chemotherapy; Albumin to globulin ratio; C-REACTIVE PROTEIN; LONG-TERM MORTALITY; 1ST-LINE TREATMENT; PROGNOSTIC-FACTOR; POOR SURVIVAL; INFLAMMATION; FLUOROURACIL; OXALIPLATIN; LUNG; LEUCOVORIN;

D O I：

10.1186/s12885-015-1375-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The pretreatment albumin to globulin ratio (AGR) has been reported to correlate with the long-term survival in patients with various cancers. However, there are no reports regarding the correlation between the pretreatment AGR and chemotherapeutic outcomes in patients with unresectable metastatic colorectal cancer. The aim of this study was to evaluate the prognostic significance of the pretreatment AGR in patients with unresectable metastatic colorectal cancer. Methods: A total of 66 patients with unresectable metastatic colorectal cancer who underwent palliative chemotherapy for metastatic tumors were enrolled. The AGR was calculated as follows: Albumin/(Total protein - Albumin). Results: The median pretreatment AGR was 1.254 (range: 0.849-1.840). We set 1.25 as the cut-off value based on the receiver operating characteristic curve. Based on the cut-off value of 1.25, 34 patients were classified into the high-AGR group and 32 patients were classified into the low-AGR group. The high-AGR group had a significantly higher chemotherapeutic disease control rate (p = 0.040) and better progression-free survival (p = 0.0171) and overall survival (p = 0.0360) rates than the low-AGR group. According to a multivariate analysis of survival, the AGR was identified to be an independent prognostic factor for progression-free survival (Hazard Ratio: 2.662, 95% Confidence Interval: 1.085-6.631, p = 0.033) and overall survival (Hazard Ratio: 2.247, 95% Confidence Interval: 1.069-4.722, p = 0.033). Conclusions: The pretreatment AGR is a useful prognostic marker in patients with unresectable metastatic colorectal cancer who receive palliative chemotherapy.

引用

页数：8

共 27 条

[1] The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer [J].

Azab, Basem ;

Kedia, Shiksha ;

Shah, Neeraj ;

Vonfrolio, Steven ;

Lu, William ;

Naboush, Ali ;

Mohammed, Farhan ;

Bloom, Scott W. .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2013, 28 (12) :1629-1636

[2] Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients [J].

Azab, Basem N. ;

Bhatt, Vijaya R. ;

Vonfrolio, Steven ;

Bachir, Rana ;

Rubinshteyn, Vladimir ;

Alkaied, Homam ;

Habeshy, Ayman ;

Patel, Jignesh ;

Picon, Antonio I. ;

Bloom, Scott W. .

AMERICAN JOURNAL OF SURGERY, 2013, 206 (05) :764-770

[3] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[4] Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas [J].

Boonpipattanapong, Teeranut ;

Chewatanakornkul, Siripong .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2006, 40 (07) :592-595

[5] Inhibition of albumin synthesis in chronic diseases - Molecular mechanisms [J].

Chojkier, M .

JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (04) :S143-S146

[6] Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability [J].

Colotta, Francesco ;

Allavena, Paola ;

Sica, Antonio ;

Garlanda, Cecilia ;

Mantovani, Alberto .

CARCINOGENESIS, 2009, 30 (07) :1073-1081

[7] Inflammation and cancer [J].

Coussens, LM ;

Werb, Z .

NATURE, 2002, 420 (6917) :860-867

[8] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[9] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[10] Albumin-globulin Ratio for Prediction of Long-term Mortality in Lung Adenocarcinoma Patients [J].

Duran, Ayse Ocak ;

Inanc, Mevlude ;

Karaca, Halit ;

Dogan, Imran ;

Berk, Veli ;

Bozkurt, Oktay ;

Ozaslan, Ersin ;

Ucar, Mahmut ;

Eroglu, Celalettin ;

Ozkan, Metin .

ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (15) :6449-6453

← 1 2 3 →